Oncology
Identifying & reducing barriers to oncology clinical research at site level
Recent developments in cancer immunotherapy illustrate virtually unprecedented clinical benefit in some advanced cancer patients, and the potential for cure seems tangible. In line with transforming patient care, we have also already begun to transform drug development.
ICON conducts clinical studies in both solid and haematological tumours including breast, lung, gastric, HCC, prostate, multiple myeloma, AML, lymphoma and leukaemia.
ICON services your oncology trial can benefit from include:
- Medical Imaging Medical imaging enables improved decision making, increased efficiency, and can reduce trial costs.
- Site and Patient Recruitment ICON's proven paradigm bridges the gap between patients and clinical research sites.
- Real World Intelligence Resources and expertise to identify, generate, synthesize and communicate evidence of treatment value and safety
- FIRECREST FIRECREST digital solutions increase efficiency in clinical trials by driving site performance.
- Laboratory Services ICON provides a full range of laboratory services that are dedicated exclusively to clinical development.
- Value Access and Outcomes Our consultants can advise you on developing market access and pricing strategies.
Medical Imaging
Medical imaging enables improved decision making, increased efficiency, and can reduce trial costs.
Site and Patient Recruitment
ICON's proven paradigm bridges the gap between patients and clinical research sites.
Real World Intelligence
Resources and expertise to identify, generate, synthesize and communicate evidence of treatment value and safety
FIRECREST
FIRECREST digital solutions increase efficiency in clinical trials by driving site performance.
Laboratory Services
ICON provides a full range of laboratory services that are dedicated exclusively to clinical development.
Value Access and Outcomes
Our consultants can advise you on developing market access and pricing strategies.
Transforming patient outcomes
The explosion of information about the genetic aberrations underlying cancer has led to several changes in the paradigm of how we develop drugs for this disease. We believe that transformation of the outcomes for patients with cancer will require detailed understanding of these genetic aberrations in each patient’s cancer at diagnosis.
Targeted therapies, novel immunotherapies and the ability to combine these agents together successfully will be important in the development of effective and tolerable treatment regimens.
Oncology insights
ICON's Oncology experts provide analysis including whitepapers, blogs and contributions to media and industry conversations relating to all aspects of oncology in clinical trials.